MEDVi vs Shed: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

52 providers verified independently·Independent research·How we rank →

Visit Shed - our pick of these two→or find your match

Shed beats MEDVi overall, scoring 7.8/10 vs 7.7/10. MEDVi is more affordable at $179/mo vs $199/mo. Choose MEDVi for users who want a low entry price with oral and injectable co. Choose Shed for users who want fast delivery and a streamlined compounded gl.

A side-by-side look at MEDVi and Shed to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

MEDVi

#20 of 52

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake, one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Higher Rated

Shed

#15 of 52

7.8/10

Newer GLP-1 provider focused on speed and simplicity, fast approvals, fast shipping, and a clean user experience at a competitive price point.

Visit Shed

Feature	MEDVi	Shed
Our Score	7.7/10	7.8/10
Starting Price	$179/mo	$199/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Users who want a low entry price with oral and injectable compounded options	Users who want fast delivery and a streamlined compounded GLP-1 experience
Ranking	#20	#15
Get started	Visit MEDVi	Visit Shed

Pros & Cons Compared

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−No brand-name Wegovy or Zepbound on the platform (the 2026 expansion added branded Ozempic only)
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms; you can switch to injectable anytime at no extra fee if results lag

Shed

Pros

+Industry-leading delivery speed, most patients receive medication within 2-3 days of enrollment
+$199/mo is competitively priced for an all-inclusive compounded program with good support
+Streamlined onboarding with no video call, approved and shipped faster than most competitors
+Clean, modern UX with real-time shipping tracking and easy provider messaging

Cons

−The core $199 program is compounded semaglutide and tirzepatide; brand-name access runs through a separate $99/mo pathway subscription with medication billed at pharmacy rates on top
−Newer company (founded 2024) with limited long-term track record and outcome data; the 4.6/5 Trustpilot rating across 766 reviews is the strongest early evidence available
−No insurance billing and no FSA/HSA superbills currently available
−Clinical support is responsive (replies typically within 24 hours) but less proactive than premium platforms; a $49.99/mo premium coaching add-on covers those who want higher touch

Our Verdict

Shed edges out MEDVi with a score of 7.8/10 vs 7.7/10. If budget is your priority, MEDVi starts at $179/mo compared to Shed's $199/mo. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options. Choose Shed if you want: users who want fast delivery and a streamlined compounded glp-1 experience.

Still undecided? Editor's Featured Pick

Yucca Health

$146/mo · 7.7/10 · Compounded

If neither MEDVi nor Shed feels like the right fit, our featured pick across all 52 GLP-1 telehealth providers is Yucca Health. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $146/mo that stays the same at every dose.

Visit Yucca Health→Read our full Yucca Health review